Chen Z D, Ye W B, Zeng W R, Song C, Song W, Zhang Y M, Wu J
Orthopaedics Center of PLA, the 909th Hospital of PLA, the Affiliated Southeast Hospital of Xiamen University, Zhangzhou 363000, China.
Department of Orthopedics, the Second Affiliated Hospital of Nanchang University, Nanchang 330000, China.
Zhonghua Zhong Liu Za Zhi. 2019 May 23;41(5):338-345. doi: 10.3760/cma.j.issn.0253-3766.2019.05.004.
To detect the effect and regulatory mechanism of human ether à go-go related gene 1 (Herg 1) knockdown on the proliferation and invasion of osteosarcoma (OS). We constructed a recombinant adenovirus vector (Ad5-Herg1-shRNA) expressing short hair RNA (shRNA) against Herg1 and tested the knockdown efficiency. Then, the effects of Herg 1 knockdown on the proliferation, growth and invasion of osteosarcoma were measured by using cell counting kit-8 (CCK-8), wound healing assay, Transwell assay and xenograft model of nude mice, respectively. Tandem affinity purification, mass spectrometry and dual luciferase reporter assay were used to find out the molecules interacted with Herg1. Western blot was used to detect the expressions of large tumor suppressor gene (LATS1), p-LATS1, Yes-associated protein (YAP) and p-YAP in cells after infection of Ad5-Herg1-shRNA. Compared to Ad5-control-shRNA, Ad5-Herg1-shRNA dramatically inhibited the expression of Herg1 in OS cells. The result of CCK8 array demonstrated that 143B cell vitalities of Ad5-Herg1-shRNA1 and Ad5-Herg1-shRNA2 group were (65.47±3.90)% and (79.90±1.52)%, significantly lower than (100.00±6.14)% of Ad5-control-shRNA group. Meanwhile, U2OS cell vitality of Ad5-Herg1-shRNA1 and Ad5-Herg1-shRNA2 group were (69.69±1.36)% and (76.72±2.75)%, significantly lower than (100.00±3.01)% of Ad5-control-shRNA group (all <0.001). The results of wound healing array showed that 143B cell migration rates of Ad5-Herg1-shRNA1 and Ad5-Herg1-shRNA2 group were (33.03±2.88)% and (36.47±4.16)%, significantly lower than (97.78±2.28)% of Ad5-control-shRNA group. Meanwhile, U2OS cell migration rates of Ad5-Herg1-shRNA1 and Ad5-Herg1-shRNA2 group were (68.07±0.90)% and (73.97±1.25)%, significantly lower than (96.50±1.12)% of Ad5-control-shRNA group (all <0.001). The results of Transwell showed that 143B cell invasion numbers of Ad5-Herg1-shRNA1 and Ad5-Herg1-shRNA2 group were 36.50±12.15 and 44.83±7.62, significantly lower than 195.33±19.68 of Ad5-control-shRNA group. Meanwhile, U2OS cell migration rates of Ad5-Herg1-shRNA1 and Ad5-Herg1-shRNA2 group were 21.83±7.99 and 22.85±7.08, significantly lower than 83.33±12.36 of Ad5-control-shRNA group (all <0.001). The results of xenograft model of OS showed that the tumor volume and weight of Ad5-Herg1-shRNA group were significantly smaller than of Ad5-control-shRNA group after 14 days and 5 weeks of inoculation, respectively (<0.001). Moreover, knockdown of Herg1 inhibited the metastasis of OS cells. In mechanism, Herg1 protein interacted with NF2 protein. Knockdown of Herg1 significantly suppressed the expression levels of LATS1 and YAP protein, and promoted the phosphorylation of LATS1 and YAP in OS cells (all <0.001). Our findings suggest that Herg1 participates in the proliferation and motility of OS cells and may serve as a potential therapeutic target for osteosarcoma patients.
检测人醚 - 去极化相关基因1(Herg 1)敲低对骨肉瘤(OS)增殖和侵袭的影响及调控机制。我们构建了表达针对Herg1的短发夹RNA(shRNA)的重组腺病毒载体(Ad5 - Herg1 - shRNA)并检测敲低效率。然后,分别使用细胞计数试剂盒 - 8(CCK - 8)、伤口愈合试验、Transwell试验和裸鼠异种移植模型来检测Herg 1敲低对骨肉瘤增殖、生长和侵袭的影响。采用串联亲和纯化、质谱分析和双荧光素酶报告基因测定法来找出与Herg1相互作用的分子。用蛋白质免疫印迹法检测感染Ad5 - Herg1 - shRNA后细胞中大型肿瘤抑制基因(LATS1)、p - LATS1、Yes相关蛋白(YAP)和p - YAP的表达。与Ad5 - 对照 - shRNA相比,Ad5 - Herg1 - shRNA显著抑制了OS细胞中Herg1的表达。CCK8检测结果表明,Ad5 - Herg1 - shRNA1组和Ad5 - Herg1 - shRNA2组的143B细胞活力分别为(65.47±3.90)%和(79.90±1.52)%,显著低于Ad5 - 对照 - shRNA组的(100.00±6.14)%。同时,Ad5 - Herg1 - shRNA1组和Ad5 - Herg1 - shRNA2组的U2OS细胞活力分别为(69.69±1.36)%和(76.72±2.75)%,显著低于Ad5 - 对照 - shRNA组的(100.00±3.01)%(均<0.001)。伤口愈合试验结果显示,Ad5 - Herg1 - shRNA1组和Ad5 - Herg1 - shRNA2组的143B细胞迁移率分别为(33.03±2.88)%和(36.47±4.16)%,显著低于Ad5 - 对照 - shRNA组的(97.78±2.28)%。同时,Ad5 - Herg1 - shRNA1组和Ad5 - Herg1 - shRNA2组的U2OS细胞迁移率分别为(68.07±0.90)%和(73.97±1.25)%,显著低于Ad5 - 对照 - shRNA组的(96.50±1.12)%(均<0.001)。Transwell试验结果显示,Ad5 - Herg1 - shRNA1组和Ad5 - Herg1 - shRNA2组的143B细胞侵袭数分别为36.50±12.15和44.83±7.62,显著低于Ad5 - 对照 - shRNA组的195.33±19.68。同时,Ad5 - Herg1 - shRNA1组和Ad5 - Herg1 - shRNA2组的U2OS细胞迁移率分别为21.83±7.99和22.85±7.08,显著低于Ad5 - 对照 - shRNA组的83.33±12.36(均<0.001)。骨肉瘤异种移植模型结果显示,接种14天和5周后,Ad5 - Herg1 - shRNA组的肿瘤体积和重量均显著小于Ad5 - 对照 - shRNA组(<0.001)。此外,敲低Herg1抑制了OS细胞的转移。机制上,Herg1蛋白与NF2蛋白相互作用。敲低Herg1显著抑制了OS细胞中LATS1和YAP蛋白的表达水平,并促进了LATS1和YAP的磷酸化(均<0.001)。我们的研究结果表明,Herg1参与OS细胞的增殖和运动,可能是骨肉瘤患者潜在的治疗靶点。